1. Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay
- Author
-
Sophia Hober, Cecilia Hellström, Jennie Olofsson, Eni Andersson, Sofia Bergström, August Jernbom Falk, Shaghayegh Bayati, Sara Mravinacova, Ronald Sjöberg, Jamil Yousef, Lovisa Skoglund, Sara Kanje, Anna Berling, Anne‐Sophie Svensson, Gabriella Jensen, Henric Enstedt, Delaram Afshari, Lan Lan Xu, Martin Zwahlen, Kalle vonFeilitzen, Leo Hanke, Ben Murrell, Gerald McInerney, Gunilla B Karlsson Hedestam, Christofer Lendel, Robert G Roth, Ingmar Skoog, Elisabet Svenungsson, Tomas Olsson, Anna Fogdell‐Hahn, Ylva Lindroth, Maria Lundgren, Kimia T Maleki, Nina Lagerqvist, Jonas Klingström, Rui Da Silva Rodrigues, Sandra Muschiol, Gordana Bogdanovic, Laila Sara Arroyo Mühr, Carina Eklund, Camilla Lagheden, Joakim Dillner, Åsa Sivertsson, Sebastian Havervall, Charlotte Thålin, Hanna Tegel, Elisa Pin, Anna Månberg, My Hedhammar, and Peter Nilsson
- Subjects
COVID‐19 ,IgG ,multiplex ,SARS‐CoV‐2 ,serological assay ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Objective The COVID‐19 pandemic poses an immense need for accurate, sensitive and high‐throughput clinical tests, and serological assays are needed for both overarching epidemiological studies and evaluating vaccines. Here, we present the development and validation of a high‐throughput multiplex bead‐based serological assay. Methods More than 100 representations of SARS‐CoV‐2 proteins were included for initial evaluation, including antigens produced in bacterial and mammalian hosts as well as synthetic peptides. The five best‐performing antigens, three representing the spike glycoprotein and two representing the nucleocapsid protein, were further evaluated for detection of IgG antibodies in samples from 331 COVID‐19 patients and convalescents, and in 2090 negative controls sampled before 2020. Results Three antigens were finally selected, represented by a soluble trimeric form and the S1‐domain of the spike glycoprotein as well as by the C‐terminal domain of the nucleocapsid. The sensitivity for these three antigens individually was found to be 99.7%, 99.1% and 99.7%, and the specificity was found to be 98.1%, 98.7% and 95.7%. The best assay performance was although achieved when utilising two antigens in combination, enabling a sensitivity of up to 99.7% combined with a specificity of 100%. Requiring any two of the three antigens resulted in a sensitivity of 99.7% and a specificity of 99.4%. Conclusion These observations demonstrate that a serological test based on a combination of several SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay.
- Published
- 2021
- Full Text
- View/download PDF